{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T17:24:03Z","timestamp":1769189043498,"version":"3.49.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Drug Policy"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.drugpo.2019.05.014","type":"journal-article","created":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T08:41:10Z","timestamp":1559292070000},"page":"189-194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Reinfection in a large cohort of prison inmates with sustained virological response after treatment of chronic hepatitis C in Catalonia (Spain), 2002\u20132016"],"prefix":"10.1016","volume":"72","author":[{"given":"Andr\u00e9s","family":"Marco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael A.","family":"Guerrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercedes","family":"Vergara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Gallego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Concepci\u00f3","family":"Sol\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram\u00f3n","family":"Planella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Elisa","family":"Vaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N\u00faria","family":"Teixid\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Sastre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Touz\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Almada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Ru\u00edz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan A.","family":"Cayl\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabet","family":"Turu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.drugpo.2019.05.014_bib0005","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1093\/cid\/cit306","article-title":"Treatment of hepatitis C virus infection among people who are actively injecting drugs: A systematic review and meta-analysis","volume":"57","author":"Aspinall","year":"2013","journal-title":"Clinical Infectious Diseases"},{"issue":"1","key":"10.1016\/j.drugpo.2019.05.014_bib0010","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1053\/jhep.2001.25882","article-title":"Treatment of hepatitis C infection in injection drug users","volume":"34","author":"Backmund","year":"2001","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.drugpo.2019.05.014_bib0015","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1086\/425361","article-title":"Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users","volume":"39","author":"Backmund","year":"2004","journal-title":"Clinical Infectious Diseases"},{"issue":"7","key":"10.1016\/j.drugpo.2019.05.014_bib0020","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1440-1746.2010.06295.x","article-title":"High prevalence of late relapse and reinfection in prisoners treated for chronic hepatitis C","volume":"25","author":"Bate","year":"2010","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"10","key":"10.1016\/j.drugpo.2019.05.014_bib0025","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1377\/hlthaff.2016.0296","article-title":"New hepatitis C drugs are very costly and unavailable to many state prisoners","volume":"35","author":"Beckman","year":"2016","journal-title":"Health Affairs (Millwood)"},{"issue":"10","key":"10.1016\/j.drugpo.2019.05.014_bib0030","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1365-2893.2008.01010.x","article-title":"Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients","volume":"15","author":"Bruggmann","year":"2008","journal-title":"Journal of Viral Hepatitis"},{"key":"10.1016\/j.drugpo.2019.05.014_bib0035","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jsat.2015.05.001","article-title":"Risk factors for relapse and higher costs among medicaid members with opioid dependence or abuse: Opioid agonists, comorbidities, and treatment history","volume":"57","author":"Clark","year":"2015","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"suppl 5","key":"10.1016\/j.drugpo.2019.05.014_bib0040","doi-asserted-by":"crossref","first-page":"S336","DOI":"10.1086\/427449","article-title":"Follow-up studies of treatment for hepatitis C virus infection among injection drug users","volume":"40","author":"Dalgard","year":"2005","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.drugpo.2019.05.014_bib0045","series-title":"Descriptors estad\u00edstics serveis penitenciaris","author":"Direcci\u00f3 General de Serveis Penitenciaris","year":"2018"},{"issue":"2","key":"10.1016\/j.drugpo.2019.05.014_bib0050","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3109\/10826084.2015.1092991","article-title":"High prevalence and Incidence of HIV and HCV among new injecting drug users with a large proportion of migrants--Is prevention failing?","volume":"51","author":"Folch","year":"2016","journal-title":"Substance Use & Misuse"},{"issue":"11","key":"10.1016\/j.drugpo.2019.05.014_bib0055","first-page":"1302","article-title":"Low incidence of reinfection with the hepatitis C virus following treatment in active drug users in Amsterdam","volume":"24","author":"Grady","year":"2012","journal-title":"European Journal of Gastroenterology & Hepatology"},{"issue":"5","key":"10.1016\/j.drugpo.2019.05.014_bib0060","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/hep.21376","article-title":"Hepatitis C virus reinfection in injection drug users","volume":"44","author":"Grebely","year":"2006","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.drugpo.2019.05.014_bib0065","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1111\/j.1440-1746.2007.05032.x","article-title":"Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users","volume":"22","author":"Grebely","year":"2007","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"7","key":"10.1016\/j.drugpo.2019.05.014_bib0070","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1111\/j.1440-1746.2010.06238.x","article-title":"Reinfection with hepatitis C virus following sustained virological response in injection drug users","volume":"25","author":"Grebely","year":"2010","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"4","key":"10.1016\/j.drugpo.2019.05.014_bib0075","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/hep.24754","article-title":"Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection","volume":"55","author":"Grebely","year":"2012","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.drugpo.2019.05.014_bib0080","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nrgastro.2017.106","article-title":"Direct-acting antiviral agents for HCV infection affecting people who inject drugs","volume":"14","author":"Grebely","year":"2017","journal-title":"Nature Reviews Gastroenterology & Hepatology"},{"issue":"1","key":"10.1016\/j.drugpo.2019.05.014_bib0085","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/infdis\/jit541","article-title":"Sequence analysis of hepatitis C virus from patients with relapse after a sustained virological response: relapse or reinfection?","volume":"209","author":"Hara","year":"2014","journal-title":"The Journal of Infectious Diseases"},{"issue":"6","key":"10.1016\/j.drugpo.2019.05.014_bib0090","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/QCO.0000000000000216","article-title":"Hepatitis C virus treatment as prevention in people who inject drugs: Testing the evidence","volume":"28","author":"Hickman","year":"2015","journal-title":"Current Opinion in Infectious Diseases"},{"issue":"suppl 2","key":"10.1016\/j.drugpo.2019.05.014_bib0095","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1093\/cid\/cit327","article-title":"Directly observed pegylated interferon plus self-administered ribavirin for the treatment of hepatitis C virus infection in people actively using drugs: A randomized controlled trial","volume":"57","author":"Hilsden","year":"2013","journal-title":"Clinical Infectious Diseases"},{"issue":"3","key":"10.1016\/j.drugpo.2019.05.014_bib0100","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S2468-1253(16)30182-0","article-title":"Incidence, risk factors, and prevention of hepatitis C reinfection: A population-based cohort study","volume":"2","author":"Islam","year":"2017","journal-title":"The Lancet Gastroenterology & Hepatology"},{"issue":"1","key":"10.1016\/j.drugpo.2019.05.014_bib0105","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jhep.2013.03.008","article-title":"Hepatitis C virus reinfection among prisoners with sustained virological response after treatment for chronic hepatitis C","volume":"59","author":"Marco","year":"2013","journal-title":"Journal of Hepatology"},{"issue":"11","key":"10.1016\/j.drugpo.2019.05.014_bib0110","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1111\/jvh.12940","article-title":"Comparison of effectiveness and discontinuation of interferon-free therapy for hepatitis C in prison inmates and non-inmates","volume":"25","author":"Marco","year":"2018","journal-title":"Journal of Viral Hepatitis"},{"issue":"4","key":"10.1016\/j.drugpo.2019.05.014_bib0115","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/jvh.12338","article-title":"HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: Real world results and modelling of treatment impact","volume":"22","author":"Martin","year":"2015","journal-title":"Journal of Viral Hepatitis"},{"issue":"5","key":"10.1016\/j.drugpo.2019.05.014_bib0120","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/jvh.12666","article-title":"HCV reinfection incidence among individuals treated for recent infection","volume":"24","author":"Martinello","year":"2017","journal-title":"Journal of Viral Hepatitis"},{"issue":"2","key":"10.1016\/j.drugpo.2019.05.014_bib0125","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.idc.2018.02.003","article-title":"Strategies to reduce hepatitis C virus reinfection in people who inject drugs","volume":"32","author":"Martinello","year":"2018","journal-title":"Infectious Disease Clinics of North America"},{"key":"10.1016\/j.drugpo.2019.05.014_bib0130","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.drugpo.2017.05.040","article-title":"Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study","volume":"47","author":"Midgard","year":"2017","journal-title":"The International Journal of Drug Policy"},{"issue":"5","key":"10.1016\/j.drugpo.2019.05.014_bib0135","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.jhep.2016.01.001","article-title":"Hepatitis C reinfection after sustained virological response","volume":"64","author":"Midgard","year":"2016","journal-title":"Journal of Hepatology"},{"issue":"5","key":"10.1016\/j.drugpo.2019.05.014_bib0140","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jinf.2015.07.006","article-title":"Hepatitis C virus reinfection after sustained virological response in HIV-infected patients with chronic hepatitis C","volume":"71","author":"Pineda","year":"2015","journal-title":"The Journal of Infection"},{"issue":"1","key":"10.1016\/j.drugpo.2019.05.014_bib0145","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/biomet\/67.1.145","article-title":"Chi-squared goodness-of-fit tests for the proportional hazards regression model","volume":"67","author":"Schoenfeld","year":"1980","journal-title":"Biometrika"},{"issue":"6","key":"10.1016\/j.drugpo.2019.05.014_bib0150","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/cid\/civ948","article-title":"Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis","volume":"62","author":"Simmons","year":"2016","journal-title":"Clinical Infectious Diseases"},{"issue":"18","key":"10.1016\/j.drugpo.2019.05.014_bib0155","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1503\/cmaj.109-5181","article-title":"Federal inmates treated for hep C drop 29%","volume":"187","author":"Webster","year":"2015","journal-title":"Canadan Medical Association Journal"}],"container-title":["International Journal of Drug Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955395919301367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955395919301367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T10:59:41Z","timestamp":1566903581000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955395919301367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":31,"alternative-id":["S0955395919301367"],"URL":"https:\/\/doi.org\/10.1016\/j.drugpo.2019.05.014","relation":{},"ISSN":["0955-3959"],"issn-type":[{"value":"0955-3959","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reinfection in a large cohort of prison inmates with sustained virological response after treatment of chronic hepatitis C in Catalonia (Spain), 2002\u20132016","name":"articletitle","label":"Article Title"},{"value":"International Journal of Drug Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugpo.2019.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}